ADORA2A and neoplasm: On this basis, we developed an A2AR inhibitor‐loaded polydopamine nanocarrier masked by an acid‐sensitive PEG shell to enable tumor‐specific delivery and PTT‐enhanced ICD immunotherapy simultaneously.